ClinicalTrials.gg
RecruitingNCT07445087Updated Oct 15, 2026

A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in South Korea

An observational study in Hereditary Angioedema (HAE), sponsored by Takeda. Recruiting at 3 sites in South Korea. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Takeda · Observational

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 15, 2026Now RecruitingFirst site in South Korea+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
35
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 58 studies in Angioedemas, Hereditary by Takeda — 3 open to participants now, 4 under way, none of them phase 3. Angioedemas, Hereditary · Takeda.

Planned enrollment
19th of 21
35 · median 83
Started
2026
with 3 others
Observational
21 of 58
2 open now
Registered
58th of 58
by date

Among the 58 studies in Angioedemas, Hereditary by Takeda, this one is the 19th largest by planned enrollment of the 21 observational ones that give a count, is one of 4 that started in 2026, is one of 21 observational ones, and was the 58th registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

3 of the 58 studies in Angioedemas, Hereditary by Takeda are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Angioedemas, Hereditary by Takeda, or all of them as a file.
02

Study summary

Takhzyro is an approved treatment for hereditary angioedema (HAE) in South Korea. HAE is a rare condition which causes sudden swelling under the skin and inside the body, like in the belly, throat, or genitals. The main aim of this study is to check how safe Takhzyro is in teenagers and adults with HAE in everyday medical care in South Korea. Another aim is to see how well Takhzyro works in everyday medical care.

The treatment of participants and any check-ups will be determined by the treating doctors according to their normal practice. Participants may visit the study clinic several times during the study.

03

Conditions studied

  • Hereditary Angioedema (HAE)

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants diagnosed with HAE who are currently receiving Takhzyro or who initiate Takhzyro treatment for the first time.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants aged 12 years or older at time of initiation of Takhzyro.
  2. Participants who are treated or will be treated with Takhzyro according to the approved label of South Korea.
  3. The participant or legally authorized representative agrees to participate.

Exclusion criteria

Exclusion criteria:

  1. Any of the included in the Prescribing Information (PI) for TAKHZYRO apply.
  2. Participant is currently enrolled in an interventional trial.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
35 participants (estimated)
Patient registry
No

Groups and cohorts

  • All Participants

    Adolescent and adult participants diagnosed with HAE who are receiving Takhzyro or initiating Takhzyro treatment for the first time in routine clinical practice will be included. Both retrospective and prospective data will be collected for up to 6 years. Treatment and follow-up will be determined by the treating physicians according to routine clinical practice.

    Other: No intervention

Interventions

  • OtherNo intervention

    This is a non-interventional study.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is any untoward medical occurrence in a study participant administered a medicinal product and which does not necessarily have to have a causal relationship with this treatment. SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events.

    Time frame: Up to approximately 12 months

  2. Number of Participants With Expected and Unexpected AEs and SAEs

    Unexpected AE is defined as AE that differs from the information in the product label in nature, severity, specificity, or outcome.

    Time frame: Up to approximately 12 months

  3. Number of Participants With Adverse Drug Reactions (ADRs), Expected and Unexpected ADRs, Serious ADRs (SADRs), Expected and Unexpected SADRs

    An ADR is an AE for which there is at least a reasonable suspicion of a causal relationship between an AE and a suspected medicinal product. Unexpected ADR is defined as an ADR that differs from the information in the ADR section of the product label in nature, severity, specificity, or outcome.

    Time frame: Up to approximately 12 months

Secondary outcomes

  1. Number of HAE Attacks

    Number of HAE attacks will be estimated across the pre- and post-treatment periods.

    Time frame: Up to approximately 12 months

  2. Monthly HAE Attack Rate

    Monthly HAE attack rate is defined as the number of HAE attacks collected from each study participant, adjusted to 28 days (1 month).

    Time frame: Up to approximately 12 months

  3. Number of HAE Attacks Requiring Acute Treatment

    Number of HAE attacks requiring acute treatment will be reported.

    Time frame: Up to approximately 12 months

  4. Monthly HAE Attack Rate Requiring Acute Treatment

    Monthly HAE attack rate requiring acute treatment will be reported.

    Time frame: Up to approximately 12 months

  5. Number of Moderate or Severe HAE Attacks

    Number of participants with HAE attack based on attack severity (Mild, moderate or severe) will be reported.

    Time frame: Up to approximately 12 months

  6. Monthly HAE Attack Rate With Moderate or Severe Severity

    Monthly HAE attack rate with moderate or severe severity will be reported.

    Time frame: Up to approximately 12 months

  7. Change From Baseline in the Monthly HAE Attack Rate

    Change from baseline in the monthly HAE attack rate will be reported.

    Time frame: Up to approximately 12 months

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Feb 2032, 65 months after the start.

Of 27 observational studies under Angioedemas, Hereditary, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 52. This study's planned 65 months is above that.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Sep 2026, on Oct 15, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2026
First posted
Mar 3, 2026
StartActual
Sep 21, 2026was Oct 2026
Primary completionEst.
Feb 29, 2032
CompletionEst.
Feb 29, 2032
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 15, 2026
Sites
3 sites added — first site in South Korea
Show 3 added (3 South Korea)
  • Ajou University Hospital · Suwon, South Korea
  • Seoul National University Hospital · Seoul, South Korea
  • Ewha Womans University Hospital · Seoul, South Korea
Oct 15, 2026
Start date
Oct 1, 2026→Sep 21, 2026 (actual)
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Not yet recruiting→Recruiting
    3 sites added — first site in South Korea
    Show 3 added (3 South Korea)
    • Ajou University Hospital · Suwon, South Korea
    • Seoul National University Hospital · Seoul, South Korea
    • Ewha Womans University Hospital · Seoul, South Korea
    Start date Oct 1, 2026→Sep 21, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07445087
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Mar 3, 2026
Start date
Sep 21, 2026
Primary completion
Feb 29, 2032 (estimated)
Completion
Feb 29, 2032 (estimated)
Last update
Oct 15, 2026

Study contacts

Takeda Contact
Contact
medinfoUS@takeda.com
+1-877-825-3327
Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion